Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATCH Subprotocol H: Dabrafenib and Trametinib in BRAF V600-Mutated Tumors
NCT04439292Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2016
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in lymphoma, Solid neoplasm, multiple myeloma (MM), sponsored by National Cancer Institute. Started Jan 2016; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
lymphomaSolid neoplasmmultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04439292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439292.